Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have been given an average rating of "Buy" by the eight research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $23.29.
Separately, JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th.
Read Our Latest Research Report on enGene
Hedge Funds Weigh In On enGene
Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in enGene during the 4th quarter valued at $93,000. Toronto Dominion Bank bought a new position in shares of enGene during the fourth quarter worth about $97,000. Cubist Systematic Strategies LLC grew its stake in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after purchasing an additional 2,080 shares in the last quarter. Corton Capital Inc. bought a new stake in enGene in the fourth quarter valued at about $157,000. Finally, ADAR1 Capital Management LLC acquired a new stake in enGene during the first quarter valued at approximately $107,000. Hedge funds and other institutional investors own 64.16% of the company's stock.
enGene Stock Up 3.0%
ENGN stock traded up $0.11 during trading on Friday, reaching $3.79. 44,123 shares of the company traded hands, compared to its average volume of 123,343. The business has a 50 day simple moving average of $3.60 and a 200 day simple moving average of $4.86. enGene has a 12 month low of $2.65 and a 12 month high of $11.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 12.66 and a quick ratio of 12.66.
enGene (NASDAQ:ENGN - Get Free Report) last issued its quarterly earnings results on Tuesday, June 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03). Analysts forecast that enGene will post -1.56 EPS for the current year.
About enGene
(
Get Free ReportenGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
